# Stylianos Antonarakis
Stylianos E. Antonarakis is a Swiss-based human geneticist, professor and chairman of Genetic Medicine (now emeritus) at the University of Geneva Medical School, a specialist in the biology of chromosome 21 and [Down syndrome](https://www.edgepedia.org/down-syndrome), a past president of the Human Genome Organization (HUGO), and the president of Medigenome SA, a Geneva genetics diagnostics company.[1](https://business-monitor.ch/fr/companies/929132-medigenome-sa) • [2](https://www.unige.ch/apropos/prix-distinctions-nominations/stylianos-antonarakis-laureat-du-william-allan-award-2019) The American Society of Human Genetics awarded him the William Allan Award in 2019 for lifetime contributions to genomic medicine.[2](https://www.unige.ch/apropos/prix-distinctions-nominations/stylianos-antonarakis-laureat-du-william-allan-award-2019)
| Fact | Detail |
|---|---|
| Field | Human genetics; chromosome 21, Down syndrome, Mendelian disease genomics[2](https://www.unige.ch/apropos/prix-distinctions-nominations/stylianos-antonarakis-laureat-du-william-allan-award-2019) |
| Training | MD 1975, DSc 1982, University of Athens; Johns Hopkins medical genetics with Kazazian and McKusick, 1980–1983[3](https://www.dexeusfoundation.org/46dexeuscongress/speaker/stylianos-antonarakis/) |
| Geneva chair | Professor and chairman of Genetic Medicine, University of Geneva, from 1992; now emeritus (active)[3](https://www.dexeusfoundation.org/46dexeuscongress/speaker/stylianos-antonarakis/) • [2](https://www.unige.ch/apropos/prix-distinctions-nominations/stylianos-antonarakis-laureat-du-william-allan-award-2019) |
| Company | Medigenome SA ("The Swiss Institute of Genomic Medicine"), registered in Geneva in 2018, UID CHE-153.118.623, with four Swiss branches; he is President of the board[1](https://business-monitor.ch/fr/companies/929132-medigenome-sa) |
| Society roles | President, European Society of Human Genetics (2001–02); ASHG Board of Directors (2011–13); HUGO president from the 2013 Singapore summit (recorded as 2012–2017 or 2013–2017)[2](https://www.unige.ch/apropos/prix-distinctions-nominations/stylianos-antonarakis-laureat-du-william-allan-award-2019) • [4](https://www.unige.ch/actualites/archives/2012/antonarakis-hugo/) |
| Output | More than 700 papers and reviews; co-editor of the textbook *Genetics in Medicine*; laboratory participated in the Human Genome Project and ENCODE[2](https://www.unige.ch/apropos/prix-distinctions-nominations/stylianos-antonarakis-laureat-du-william-allan-award-2019) • [5](https://scholar.google.ch/citations?hl=en&user=HJyMVXoAAAAJ) |
| Major award | William Allan Award, American Society of Human Genetics, 2019[2](https://www.unige.ch/apropos/prix-distinctions-nominations/stylianos-antonarakis-laureat-du-william-allan-award-2019) |
## Early life and scientific training
Antonarakis received his MD in 1975 and his DSc in 1982 from the University of Athens Medical School, and specialized in pediatrics at the [University Hospital](https://www.edgepedia.org/university-hospital) in Athens.[3](https://www.dexeusfoundation.org/46dexeuscongress/speaker/stylianos-antonarakis/) He then moved to Baltimore for the medical genetics program at the Johns Hopkins University School of Medicine, training with [Haig H. Kazazian](https://www.edgepedia.org/haig-h-kazazian) and Victor McKusick from 1980 to 1983.[3](https://www.dexeusfoundation.org/46dexeuscongress/speaker/stylianos-antonarakis/)
Translation into clinical service began early: with Kazazian he established one of the first molecular diagnostic laboratories in the USA as early as 1982, applying recombinant DNA methods to the diagnosis of inherited disease.[3](https://www.dexeusfoundation.org/46dexeuscongress/speaker/stylianos-antonarakis/) He joined the [Johns Hopkins](https://www.edgepedia.org/johns-hopkins) faculty in 1983 and became a full professor of Pediatric Genetics, Biology, and Medicine around 1990–1991 (his society biography gives 1990; the Allan Award introduction says "by 1991"), before moving to Geneva in 1992.[3](https://www.dexeusfoundation.org/46dexeuscongress/speaker/stylianos-antonarakis/) • [6](https://www.cell.com/ajhg/fulltext/S0002-9297(20)30006-9)
## Scientific contributions
**Beta-globin and hemophilia.** His early work identified DNA polymorphisms in the beta-globin gene region used to build the first DNA haplotypes, which, in collaboration with [Stuart Orkin](https://www.edgepedia.org/stuart-orkin), led to a rational method for characterizing beta-thalassemia mutations.[6](https://www.cell.com/ajhg/fulltext/S0002-9297(20)30006-9) At Johns Hopkins he also collaborated on characterizing the molecular defects in hemophilia A, work that produced findings including active transposable elements.[6](https://www.cell.com/ajhg/fulltext/S0002-9297(20)30006-9) His laboratory is credited with discovering the etiology of many hereditary disorders, including thalassemia, hemophilia, and more than 40 others.[7](https://www.iaso.gr/en/news/details/2024/05/28/the-distinguished-scientist-stylianos-antonarakis-at-iaso)
**Chromosome 21 and Down syndrome.** His laboratory turned to characterizing the genes on chromosome 21 and their role in Down syndrome.[6](https://www.cell.com/ajhg/fulltext/S0002-9297(20)30006-9) His laboratory participated in the [Human Genome Project](https://www.edgepedia.org/human-genome-project) with particular emphasis on chromosome 21, and he is described as an international expert on disorders of chromosome 21.[8](https://www.globaldownsyndrome.org/our-story/linda-crnic-institute/linda-crinic-institute-scientific-advisory-board/stylianos-antonarakis-md-doctor-of-science/) A lasting public legacy is World Down Syndrome Day, which he originated and which has been celebrated each March 21 since 2006.[3](https://www.dexeusfoundation.org/46dexeuscongress/speaker/stylianos-antonarakis/)
**Genome-wide annotation.** He is listed among the authors of the ENCODE consortium's landmark papers, including "An integrated encyclopedia of DNA elements in the human genome" (*Nature* 489, 57, 2012) and the ENCODE pilot project paper.[5](https://scholar.google.ch/citations?hl=en&user=HJyMVXoAAAAJ)
**Mentorship.** Part of the work that led to Gregg Semenza's share of the 2019 [Nobel Prize in Physiology or Medicine](https://www.edgepedia.org/nobel-prize-in-physiology-or-medicine) was performed in Antonarakis's laboratory when Semenza was a postdoctoral fellow there.[3](https://www.dexeusfoundation.org/46dexeuscongress/speaker/stylianos-antonarakis/)
## Leadership at the University of Geneva and HUGO
In 1992 Antonarakis moved to Geneva to chair Genetic Medicine at the University of Geneva, where he developed a major clinical and laboratory genetics center and directed the department of medical genetics and the iGE3 institute of genetics and genomics in Geneva.[3](https://www.dexeusfoundation.org/46dexeuscongress/speaker/stylianos-antonarakis/) • [4](https://www.unige.ch/actualites/archives/2012/antonarakis-hugo/) • [2](https://www.unige.ch/apropos/prix-distinctions-nominations/stylianos-antonarakis-laureat-du-william-allan-award-2019) In 2014 he created a pioneer "Genome Clinic" at the University Hospitals of Geneva; the stated ambition was to sequence the genomes of 100,000 people to trace gene variations.[3](https://www.dexeusfoundation.org/46dexeuscongress/speaker/stylianos-antonarakis/) • [8](https://www.globaldownsyndrome.org/our-story/linda-crnic-institute/linda-crinic-institute-scientific-advisory-board/stylianos-antonarakis-md-doctor-of-science/)
He was president of the European Society of Human Genetics in 2001–2002 and served on the ASHG Board of Directors from 2011 to 2013.[2](https://www.unige.ch/apropos/prix-distinctions-nominations/stylianos-antonarakis-laureat-du-william-allan-award-2019) UNIGE announced his election to the HUGO presidency in 2012, to take office at the Singapore summit in early 2013 on a four-year mandate renewable twice; sources record his term as 2012–2017 or 2013–2017.[4](https://www.unige.ch/actualites/archives/2012/antonarakis-hugo/) • [2](https://www.unige.ch/apropos/prix-distinctions-nominations/stylianos-antonarakis-laureat-du-william-allan-award-2019) • [3](https://www.dexeusfoundation.org/46dexeuscongress/speaker/stylianos-antonarakis/)
His HUGO agenda had three stated planks. First, opposition to intellectual property on genes: "We are clearly against the patenting of genes, portions of the genome, or genetic diagnostic methods," he said on his election.[4](https://www.unige.ch/actualites/archives/2012/antonarakis-hugo/) Second, access, promoting the availability of medical genetics technologies in developing countries and dialogue on ethics.[4](https://www.unige.ch/actualites/archives/2012/antonarakis-hugo/) Third, integration into healthcare: he described HUGO's mission as introducing genetics and genomics into healthcare on a global scale, including collaboration with the World Health Organization to quantify the genome's role in public health.[9](https://www.jax.org/news-and-insights/jax-blog/2013/december/interview-with-stylianos)
## Business and commercial ventures
**Medigenome SA.** The Swiss commercial registry records Medigenome SA, a company in biotechnology research and development, as founded in 2018 (entry dated 08/02/2018, UID CHE-153.118.623), registered at rue Viollier 4, 1207 Genève; his congress biography describes him founding "Medigenome, The Swiss Institute of Genomic Medicine" in 2017.[1](https://business-monitor.ch/fr/companies/929132-medigenome-sa) • [3](https://www.dexeusfoundation.org/46dexeuscongress/speaker/stylianos-antonarakis/) Antonarakis is President of the board, whose other listed members include Bernard Conrad and Daniel Favre Jean; he also serves as CEO and Chief Medical Officer.[1](https://business-monitor.ch/fr/companies/929132-medigenome-sa) • [3](https://www.dexeusfoundation.org/46dexeuscongress/speaker/stylianos-antonarakis/) The company's statutory purpose covers diagnosis, screening, expertise, training, and medical consulting in genetics and forensics in Switzerland and abroad, and it operates four branches, in [Neuchâtel](https://www.edgepedia.org/neuchatel), Lausanne, Fribourg, and Vevey.[1](https://business-monitor.ch/fr/companies/929132-medigenome-sa)
**Greek Institute of Human Genomics.** In 2022 he co-founded the Greek Institute of Human Genomics, a public research institute in Athens, and serves as the first chairperson of its steering committee.[3](https://www.dexeusfoundation.org/46dexeuscongress/speaker/stylianos-antonarakis/)
## By the numbers
The scale of his academic output is large by any standard: UNIGE credits him with more than 700 papers and reviews, and his Dexeus biography with more than 750.[2](https://www.unige.ch/apropos/prix-distinctions-nominations/stylianos-antonarakis-laureat-du-william-allan-award-2019) • [3](https://www.dexeusfoundation.org/46dexeuscongress/speaker/stylianos-antonarakis/) More than 120 graduate students and postdoctoral fellows trained in his laboratory and more than 35 young physicians in his department's Medical Genetics Clinic (UNIGE counts over 80 scientists trained).[3](https://www.dexeusfoundation.org/46dexeuscongress/speaker/stylianos-antonarakis/) • [2](https://www.unige.ch/apropos/prix-distinctions-nominations/stylianos-antonarakis-laureat-du-william-allan-award-2019) On the commercial side, the registry shows a four-branch Swiss network.[1](https://business-monitor.ch/fr/companies/929132-medigenome-sa)
## How his translation path compares with NIPT peers
Antonarakis's route from research to market is an academic-to-clinic model: a university Genome Clinic, then a Swiss diagnostics company built around genetic and forensic testing services. The commercial NIPT field followed a different trajectory. Dennis Lo, who developed the underlying cell-free fetal DNA technology at the Chinese University of Hong Kong around 2007–2008, launched commercial Down syndrome NIPT in 2011, co-founded Xcelom (roughly half of Hong Kong's NIPT market) and Cirina, and saw Cirina acquired by Grail in 2017 for US$300m, with Grail later bought by Illumina for US$7.1bn.[10](https://pharmaboardroom.com/interviews/interview-y-m-dennis-lo-co-founder-cirina-professor-of-chemical-pathology-faculty-of-medicine-the-chinese-university-of-hong-kong-cuhk-hong-kong/) • [11](https://www.cpr.cuhk.edu.hk/en/press/cuhk-professor-dennis-lo-and-prenetics-establish-us200m-joint-venture-insighta-for-breakthrough-multi-cancer-early-detection-screening/) The test is now available in more than 90 countries, with over 10 million expectant mothers screened annually, in a market valued at US$7.3bn and projected to reach US$13.1bn by 2027.[10](https://pharmaboardroom.com/interviews/interview-y-m-dennis-lo-co-founder-cirina-professor-of-chemical-pathology-faculty-of-medicine-the-chinese-university-of-hong-kong-cuhk-hong-kong/) • [11](https://www.cpr.cuhk.edu.hk/en/press/cuhk-professor-dennis-lo-and-prenetics-establish-us200m-joint-venture-insighta-for-breakthrough-multi-cancer-early-detection-screening/) Antonarakis's sources connect him to molecular diagnostics and genomic medicine generally, not to NIPT specifically; his 1982 diagnostic laboratory predates NIPT by decades.
## Recent developments (2024–2026)
As Professor Emeritus (active), Antonarakis delivered the lecture "The human genome in health and disease" at IASO Hospital in Maroussi, Greece, on May 31, 2024.[7](https://www.iaso.gr/en/news/details/2024/05/28/the-distinguished-scientist-stylianos-antonarakis-at-iaso) In September 2024 he was to receive the Vexillum Sciacca 2024 Award for Medical Genetics at a Vatican ceremony on September 28.[12](https://vog.ert.gr/ondemand/Geneticist-Stylianos-Antonarakis-on-Take-Your-Time-26-Sept-2024/?lang=en) He remains board president of Medigenome SA in the Swiss registry[1](https://business-monitor.ch/fr/companies/929132-medigenome-sa) and chairperson of the Greek Institute of Human Genomics steering committee.[3](https://www.dexeusfoundation.org/46dexeuscongress/speaker/stylianos-antonarakis/)
## References
1. [Medigenome SA, Genève – business-monitor.ch (Swiss commercial registry record)](https://business-monitor.ch/fr/companies/929132-medigenome-sa)
2. [Stylianos Antonarakis lauréat du William Allan Award 2019 – UNIGE](https://www.unige.ch/apropos/prix-distinctions-nominations/stylianos-antonarakis-laureat-du-william-allan-award-2019)
3. [Stylianos Antonarakis – 46 International Dexeus Congress speaker biography](https://www.dexeusfoundation.org/46dexeuscongress/speaker/stylianos-antonarakis/)
4. [Un professeur de l'UNIGE nommé président de l'organisation du génome humain – UNIGE Actualités (2012)](https://www.unige.ch/actualites/archives/2012/antonarakis-hugo/)
5. [Stylianos E. Antonarakis – Google Scholar](https://scholar.google.ch/citations?hl=en&user=HJyMVXoAAAAJ)
6. https://www.cell.com/ajhg/fulltext/S0002-9297(20)30006-9
7. [The Distinguished Scientist Stylianos Antonarakis at IASO – IASO](https://www.iaso.gr/en/news/details/2024/05/28/the-distinguished-scientist-stylianos-antonarakis-at-iaso)
8. [Stylianos Antonarakis, MD – Global Down Syndrome Foundation](https://www.globaldownsyndrome.org/our-story/linda-crnic-institute/linda-crinic-institute-scientific-advisory-board/stylianos-antonarakis-md-doctor-of-science/)
9. [The global impact of genomics: Interview with Stylianos Antonarakis – Jackson Laboratory (2013)](https://www.jax.org/news-and-insights/jax-blog/2013/december/interview-with-stylianos)
10. [Interview: Dennis Lo, Co-Founder, Cirina – PharmaBoardroom](https://pharmaboardroom.com/interviews/interview-y-m-dennis-lo-co-founder-cirina-professor-of-chemical-pathology-faculty-of-medicine-the-chinese-university-of-hong-kong-cuhk-hong-kong/)
11. [CUHK Professor Dennis Lo and Prenetics establish US$200m joint venture Insighta – CUHK](https://www.cpr.cuhk.edu.hk/en/press/cuhk-professor-dennis-lo-and-prenetics-establish-us200m-joint-venture-insighta-for-breakthrough-multi-cancer-early-detection-screening/)
12. [Geneticist Stylianos Antonarakis on "Take Your Time" – Voice of Greece (2024)](https://vog.ert.gr/ondemand/Geneticist-Stylianos-Antonarakis-on-Take-Your-Time-26-Sept-2024/?lang=en)
---
*Topic: Encyclopedia › Society and history › Economics and business › Founders, operators, and investors › Life-science and healthcare founders and companies › Diagnostics and clinical genomics*
*Initially written Sep 19, 2026 · Reviewed: Sep 19, 2026 · Edited: Oct 15, 2026 · Last review: Sep 19, 2026*
*Copyright 2026 EdgeChat AI, a subsidiary of Biostate AI.*
License: Edgepedia Community License 1.0, https://www.edgepedia.org/edgepedia/license